{"id":4424,"date":"2019-03-26T06:39:54","date_gmt":"2019-03-26T06:39:54","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4424"},"modified":"2019-03-26T06:39:54","modified_gmt":"2019-03-26T06:39:54","slug":"evolution-a-long-terme-apres-larret-du-vemurafenib-un-inhibiteur-de-braf-dans-la-maladie-derdheim-chester-love","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/fr\/study_trials\/long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love\/","title":{"rendered":"R\u00e9sultats \u00e0 long terme apr\u00e8s l'arr\u00eat du traitement par le v\u00e9muraf\u00e9nib \/ les inhibiteurs de BRAF dans la maladie d'Erdheim-Chester (LOVE)"},"content":{"rendered":"<p><strong>Objectif de l'\u00e9tude :<\/strong> Les patients atteints d'ECD trait\u00e9s par le v\u00e9muraf\u00e9nib semblent pr\u00e9senter une stabilisation de la maladie. Cette \u00e9tude \u00e9value la possibilit\u00e9 d'une interruption du traitement. D'autres inhibiteurs de BRAF, tels que le dabraf\u00e9nib, ont r\u00e9cemment \u00e9t\u00e9 propos\u00e9s pour le traitement des histiocytoses pr\u00e9sentant une mutation du g\u00e8ne BRAF. L'interruption du traitement par d'autres inhibiteurs de BRAF devrait \u00e9galement faire l'objet d'une \u00e9valuation prospective.<\/p>\n<p><strong>Chercheur principal :<\/strong> Julien Haroche, docteur en m\u00e9decine, docteur \u00e8s sciences, H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Paris, FRANCE<\/p>\n<p><strong>Coordonn\u00e9es :<\/strong> T\u00e9l\u00e9phone : +33 1 42 17 80 37 E-mail : julien.haroche@psl.aphp.fr<\/p>\n<p><strong>Participation demand\u00e9e au patient :<\/strong> Les patients et les m\u00e9decins traitants sont invit\u00e9s \u00e0 contacter le professeur Julien Haroche pour obtenir de plus amples informations.<\/p>\n<p><strong>Identifiant ClinicalTrials.gov :<\/strong> NCT02089724<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4424","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials\/4424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=4424"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials_cat?post=4424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}